Public market insider selling at Mind Medicine (MindMed) (MMED)

Public market insider selling at Mind Medicine (E:MMED)

Stephen Hurst, a Director and 10% Holder, disposed of 500,000 Subordinate Voting Shares on a control or direction basis for registered holder Savant HWP Inc. at prices ranging from $2.210 to $2.360 between October 1st, 2021 and October 7th, 2021. This represents a $1,131,501 divestment of the company's shares and an account share holdings change of -1.2%.

Mind Medicine (MindMed) is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

Mind Medicine (MindMed) Inc. is a Canada-based clinical-stage psychedelic medicine biotechnology company. The Company focuses on discovering, developing and deploying psychedelic-inspired medicines and therapies to address addiction and mental illness. The Company's commercial drug development programs includes lysergic acid diethylamide (LSD) experiential therapy, 18-methoxycoronaridine (18-MC) opioid withdrawal, LSD microdosing, methylenedioxymethamphetamine (MDMA), and dimethyltryptamine (DMT). The Company's subsidiaries include Mind Medicine, Inc., HealthMode, Inc., MindMed Pty Ltd. and MindMed GmbH.